Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Enzo Life Sciences Introduces New Portfolio of Clinically Relevant, Validated Antibodies for IHC

Enzo Life Sciences is proud to announce the introduction of three new clinically relevant antibodies for immunohistochemistry detection. When combined with Enzo’s enhanced detection system, our IHC solutions are among the most robust and cost-effective on the market. This furthers Enzo’s capabilities in the rapidly growing segment of Anatomical Pathology, and allows us to enable the rapid and accurate reading of tissue biopsies.

Included in the launch is our p16INK4A monoclonal antibody, an antibody specific for a cyclin-dependent kinase inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between different phases of the cell cycle, p16 decelerates cellular differentiation and acts as a tumor suppressor. This implicates p16 in a number of cancers, including cervical cancer, head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some forms of leukemia.

We’re also proud to launch our HER2/Neu monoclonal antibody, an antibody specific for a proto-oncogenic trans-membrane receptor tyrosine kinase which is clinically indicated in a number of carcinomas. Overexpression of the HER2/Neu protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2/Neu and p53, another common clinically relevant marker, has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.

Finally, we are introducing our Ki-67 monoclonal antibody. Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumors, including those of the brain, breast, cervix, and prostate.

Together, these three antibodies provide us with an excellent cross-section of clinically relevant antibodies, allowing us to bring high performance and cost-effective solutions to the Anatomical Pathology market. The Anatomical Pathology market is estimated at $8.5 billion USD globally and is driven strongly by the $1.75 billion USD Immunohistochemistry market.

About Enzo Life Sciences

Enzo Life Sciences, Inc. is a wholly owned subsidiary of Enzo Biochem, Inc. headquartered in Farmingdale, New York. Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products and services that meet the ever-changing and rapidly growing needs of healthcare. Underpinning Enzo Biochem’s technologies, platforms and products is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Enzo Life Sciences, Inc. is a pioneer in labeling and detection technologies from genome to whole cell across research and diagnostic markets. We are focused on providing cost-effective, relevant and reliable solutions for life science research, drug development, and clinical research. We are organized to lead in the development, production, marketing, and sales of innovative research tools worldwide based on 40 years’ experience in building strong global market recognition and implementing outstanding operational capabilities.

New Product Release
Date: January 25th 2018

For additional Information, please contact:
Kara Cannon, Global Head of Marketing
1-631-694-7070 x 1301

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2019 Enzo Life Sciences, Inc.,